Search
Overview
Biopharma Live From the Lab 2026 was a hybrid livestream event that brought together scientists, analytical experts, and industry leaders from across APJ.
Broadcast live from Korea and connected to satellite locations in India, Indonesia, and Japan, the program highlighted how advanced analytical workflows support biopharma development, regulatory readiness, and compliant quality control across emerging biomodalities.
What You Will Learn
By watching the on-demand recording, you can explore:
- Practical strategies for biopharma workflow development and regulatory compliance
- Advanced analytical approaches for complex biologics and next-generation QC
- Insights from Thermo Fisher Scientific application experts
- Regional perspectives from the APJ biopharma community
This event featured scientific discussions focused on today's development, scale-up, and regulatory challenges. Access the recording to gain actionable insights that can help strengthen your biopharma workflow and QC strategy.
Meet the Experts
Prof. Jonathan Bones
Principal Investigator
The National Institute for Bioprocessing Research and Training (NIBRT)
Dr Jonathan Bones received his PhD in Analytical Chemistry from Dublin City University in 2007. He then transitioned to NIBRT, to Professor Pauline M. Rudd’s lab. In 2010, Dr Bones moved to the Barnett Institute of Chemical and Biological Analysis at Northeastern University, Boston, to work with Professor Barry L. Karger. In 2012, he returned to NIBRT, where he currently services as a principal investigator of the NIBRT Characterization and Comparability Laboratory. Dr Bones is also an associate professor for the School of Chemical and Bioprocess Engineering at University College Dublin.
Biopharmaceutical Characterisation Workflows Using LC-Orbitrap MS
Modern biopharmaceuticals demand analytical workflows capable of resolving increasingly complex molecular structures.
In this session, Professor Jonathan Bones shares how integrated LC-Orbitrap™ MS workflows are advancing the characterization of biosimilars, multispecific antibodies, fusion proteins, and other complex biologics. Using real-world examples, he illustrates how high-resolution chromatography, mass spectrometry, and data analysis work together to deliver deeper molecular understanding, strengthen comparability assessments, and support analytical excellence across the biopharmaceutical lifecycle.
Dr. Sara Carillo
Bioanalytical Research Lead
The National Institute for Bioprocessing Research and Training (NIBRT)
Dr. Sara Carillo completed her PhD in Chemical Sciences in 2013 at the University of Naples “Federico II” focusing on the structural characterization of polysaccharides and glycoconjugates from Gram-negative bacteria via NMR and mass spectrometry techniques. In 2015 she joined CCL group in NIBRT working on the understanding of the effects of extractables and leachables from single-use bioreactors on CHO cells N-glycome and produced monoclonal antibodies. She is now working in NIBRT as Bioanalytical Research Lead and is mainly interested in the development on new analytical approaches to ensure deeper and easier understanding of biomanufacturing process and biopharmaceuticals structural complexity.
Multi-Attribute Method (MAM): From Origin to New Horizons
Multi-Attribute Method (MAM) has evolved from an emerging analytical concept into a powerful platform for monitoring product quality throughout the biopharmaceutical lifecycle.
In this presentation, Dr. Sara Carillo explores the principles behind MAM, practical considerations for implementation, and how high-resolution mass spectrometry enables robust monitoring of critical quality attributes. Discover how MAM is expanding beyond QC release testing to support process development, biosimilarity assessment, clone selection, and lifecycle monitoring – helping laboratories improve efficiency while maintaining analytical confidence.
Xiaoxi Zhang
Application Manager, Pharma & Biopharma
Thermo Fisher Scientific
Xiaoxi Joined Thermo Fisher Scientific China in 2012. Currently she is Application Manager in Pharma and Biopharma vertical marketing team, Chromatography and Mass Spectrometry Division, Thermo Fisher Scientific. Xiaoxi is managing collaborations with China regulatory authority, biopharma KOLs. She has 10+ publications/orals/posters in biotherapeutic characterization since 2021.
Resolving ADC Heterogeneity: Comprehensive Purity and Charge Variant Analysis Using 2D-LC/MS and IEX-MS
Antibody–drug conjugates (ADCs) are among today's most complex biotherapeutics, requiring advanced analytical strategies to characterize their critical quality attributes.
In this session, Xiaoxi Zhang explores how high-resolution mass spectrometry, combined with 2D-LC/MS and ion exchange chromatography (IEX-MS), enables comprehensive analysis of ADC heterogeneity, including drug-antibody ratio (DAR), purity, charge variants, and process-related impurities. Learn how these workflows provide deeper molecular insight to support CMC development, process optimization, and regulatory confidence.
High-Resolution Impurity Profiling and Control Strategies for GLP-1 Receptor Agonists
As GLP-1 therapeutics continue to transform diabetes and obesity treatment, robust impurity characterization has become increasingly important for product quality and regulatory compliance.
In this presentation, Xiaoxi Zhang demonstrates how high-resolution LC-MS workflows can identify and characterize process-related impurities and degradation products in GLP-1 receptor agonists, including semaglutide. Through practical case studies, discover how advanced analytical approaches support impurity profiling, stability studies, and confident decision-making throughout development and quality control.